🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million new cases annually. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the highly restricted available drugs at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per data detailed in a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which uses two antibiotics. The trial enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in a wide range of developing nations.

Doctors directly involved have voiced optimism. Having a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea globally.